Loading clinical trials...
Loading clinical trials...
Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome
Conditions
Interventions
Ravulizumab
Locations
12
Japan
Research Site
Bunkyō City, Japan
Research Site
Hirakata-shi, Japan
Research Site
Iruma-Gun, Japan
Research Site
Kyoto, Japan
Research Site
Matsumoto-shi, Japan
Research Site
Miyazaki, Japan
Start Date
December 19, 2025
Primary Completion Date
June 25, 2027
Completion Date
June 25, 2027
Last Updated
April 20, 2026
NCT06312644
NCT05996731
NCT05805202
NCT06065852
NCT04889430
NCT05684159
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions